when was semaglutide patented Indian generics undercut Wegovy by as much as 87% after patent expiry What is the patent landscape

Clinical trials have shown promising results, with participants achieving an average weight loss of 15% over 68 weeks

Important Safety Reminders Medical Supervision Required: AOD-9604 should only be used under qualified medical supervision Baseline and monitoring laboratory testing is recommended Individual contraindications and health status must be evaluated AOD-9604 is not FDA-approved for any indication Contraindications and Precautions: Pregnancy and breastfeeding (no safety data available) Active malignancy (discuss with oncologist) Pediatric use (not studied in children) Significant organ dysfunction (limited safety data) Report Concerns: Any unexpected symptoms or adverse effects should be reported to your healthcare provider promptly

J.HeckerL

Tissue Eng Part A

Treatment for soft tissue sarcoma may cause side effects

However, the exact mechanism is not known (92)